Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as a subcutaneous formulation for injection use. It is employed to treat rheumatoid arthritis, psoriasis, certain cancers and ectopic pregnancy in adult patients. GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is a disease‑modifying antirheumatic drug (DMARD) that acts on rapidly dividing cells and immune pathways.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: diminishes skin lesions and plaque formation. Certain cancers (e.g., leukemia, lymphoma): interferes with cancer cell proliferation. Ectopic pregnancy: terminates abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Mouth sores (stomatitis). - Decreased blood cell counts. - Elevated liver enzymes. - Hair thinning or loss.

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infection due to bone‑marrow suppression. - Renal failure or impaired kidney function. - Anaphylactic or severe allergic reactions. - Birth defects when exposure occurs in pregnancy.

Before initiating therapy, several safety considerations are required.

Monitor liver function: perform baseline and periodic liver enzyme tests. Monitor blood counts: conduct regular complete blood count assessments. Avoid use in pregnancy: contraindicated due to teratogenic risk (Category X). Avoid live vaccines: immunosuppression may increase infection risk. Adjust dose in renal impairment: reduce dosage or increase monitoring. Store at room temperature: keep in original packaging, protect from moisture and light.

Methotrexate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - NSAIDs: increase methotrexate toxicity. - Trimethoprim: enhance myelosuppression. - Proton pump inhibitors: raise methotrexate plasma levels.

Moderate Interactions (Monitor Closely): - Azathioprine: additive immunosuppression. - Sulfasalazine: may increase hepatic effects. - Alcohol: potentiates liver injury.